Programme 2013

The webcast of the entire Resistant Hypertension Course 2013 is made possible via an unrestricted educational grant from Medtronic.

Speaker
Date
Type

13 sessions found from the search.

Friday, 15th February 2013

Fri, 15 February

10:30 - 10:45

Welcome

• Introduction

Watch session

10:30 - 10:35
Raison d'être of this Course
J. MARCO (FRANCE)
10:35 - 10:40
Course objectives and philosophy
S.E. KJELDSEN (NORWAY)
10:40 - 10:45
Vision of the European Society of Hypertension
R. CÍFKOVÁ (CZECH REPUBLIC) Presentation
 

Fri, 15 February

10:50 - 11:00

Lecture: Treatment of difficult hypertension, a global problem - moving into a new multi-disciplinary area

• Lecture

Speaker: S.E. KJELDSEN (NORWAY) Presentation

Fri, 15 February

11:00 - 12:20

My patient presents with "uncontrolled hypertension": how to rule out all spurious resistant hypertension causes?

• Main session

Watch session

Chairpersons: R. CÍFKOVÁ (CZECH REPUBLIC), F. MAHFOUD (GERMANY)
Facilitator: A. BAUMBACH (UNITED KINGDOM)
11:00 - 11:05
Introduction
R. CÍFKOVÁ (CZECH REPUBLIC)
11:05 - 11:15
A step-by-step personalised patient assessment, optimising treatment and ruling out spurious resistant hypertension causes: medical adherence
P.F. PLOUIN (FRANCE) Presentation
11:15 - 11:25
A step-by-step personalised patient assessment, optimising treatment and ruling out spurious resistant hypertension causes: true resistance
R. SCHMIEDER (GERMANY)
11:25 - 11:35
A step-by-step personalised patient assessment, optimising treatment and ruling out spurious resistant hypertension causes: lifestyle changes
P. BLANKESTIJN (NETHERLANDS) Presentation
11:35 - 11:45
A step-by-step personalised patient assessment, optimising treatment and ruling out spurious resistant hypertension causes: secondary causes
P.F. PLOUIN (FRANCE) Presentation
11:45 - 11:55
A step-by-step personalised patient assessment, optimising treatment and ruling out spurious resistant hypertension causes: spironolactone
R. SCHMIEDER (GERMANY)
11:55 - 12:20
Reaching a consensus all together: What information? How to be exhaustive and efficient? Which optimal pathway?
P. BLANKESTIJN (NETHERLANDS), F. MAHFOUD (GERMANY), R. CÍFKOVÁ (CZECH REPUBLIC), P.F. PLOUIN (FRANCE), R. SCHMIEDER (GERMANY)
 

Fri, 15 February

12:30 - 13:30

Multi-electrode Renal Denervation for Hypertension - An EnligHTN™ Approach-Industry-supported lunch symposium with an unrestricted grant from ST. JUDE MEDICAL

• Symposium

Chairperson: F. MAHFOUD (GERMANY)
12:30 - 12:33
Introduction
F. MAHFOUD (GERMANY)
12:33 - 12:51
Building clinical evidence with the multi-electrode EnligHTN™ renal denervation system
F. MAHFOUD (GERMANY) Presentation
12:51 - 13:09
The multi-disciplinary approach - Establishing the therapy in your hospital   
J. BÖRGEL (GERMANY) Presentation
13:09 - 13:27
Procedure walkthrough and real world experience
A. KALTOFT (DENMARK) Presentation
13:27 - 13:30
Take home messages
F. MAHFOUD (GERMANY)
 

Fri, 15 February

14:00 - 15:30

My patient presents with "resistant hypertension": is s/he a good candidate for renal sympathetic denervation? (session to be continued at 16:00)

• Main session

Watch session

14:00 - 14:05
Introduction
F. MAHFOUD (GERMANY)
14:00 - 15:30
S.E. KJELDSEN (NORWAY), F. MAHFOUD (GERMANY), J. MARCO (FRANCE)
14:05 - 14:20
Role of the sympathetic nervous system in hypertension and other frequent diseases
G. MANCIA (ITALY) Presentation
14:20 - 14:45
Live in-a-box® of a patients treated with renal sympathetic denervation: from patient screening to procedure
14:45 - 15:00
A patient with "long-term success": lessons learned?
C. UKENA (GERMANY) Presentation
15:00 - 15:15
"A non-responding" patient: the patient, the technique or the doctor?
J. RENKIN (BELGIUM) Presentation
 

Fri, 15 February

16:00 - 17:00

My patient presents with "resistant hypertension": is she a good candidate for renal sympathetic denervation?

• Main session

Watch session

Facilitator: J. MARCO (FRANCE)
16:00 - 16:15
A "drug non-compliant" patient: candidate to renal sympathetic denervation
P.F. PLOUIN (FRANCE) Presentation
16:00 - 17:00
F. MAHFOUD (GERMANY), S.E. KJELDSEN (NORWAY)
16:15 - 16:30
A patient with metabolic syndrome, obstructive sleep apnea and nocturnal hypertension
A. WITKOWSKI (POLAND) Presentation
16:30 - 16:45
On-going research: hypothesis for other indications beyond resistant hypertension and perspectives
R. SCHMIEDER (GERMANY)
16:45 - 17:00
Reaching a Consensus all together: Candidates and contra-indications for this new approach - Is it time to push the envelope?
S.E. KJELDSEN (NORWAY), F. MAHFOUD (GERMANY), G. MANCIA (ITALY), P.F. PLOUIN (FRANCE), J. RENKIN (BELGIUM), R. SCHMIEDER (GERMANY), A. WITKOWSKI (POLAND), C. UKENA (GERMANY)
 

Fri, 15 February

17:15 - 18:15

Renal denervation: New Symplicity™ clinical evidence from globals trials, real-world registries and beyond-Industry-supported evening symposium with an unrestricted grant from MEDTRONIC -

• Symposium

Watch session

Chairperson: M. ESLER (AUSTRALIA)
17:15 - 17:27
Update on Symplicity™ Clinical trials
M. ESLER (AUSTRALIA) Presentation
17:27 - 17:39
Clinical studies - Where to from here?
L.M. RUILOPE (SPAIN) Presentation
17:39 - 17:51
Extending to moderate hypertension
M. ESLER (AUSTRALIA) Presentation
17:51 - 18:03
Expanding to heart failure
D. FRANCIS (UNITED KINGDOM) Presentation
18:03 - 18:15
Expanding to chronic kidney disease
L.M. RUILOPE (SPAIN) Presentation
 

Saturday, 16th February 2013

Sat, 16 February

07:30 - 08:30

Innovation at the heart of renal denervation-Industry-supported breakfast symposium with an unrestricted grant from CORDIS

• Symposium

Chairperson: F. MAHFOUD (GERMANY)
07:30 - 07:33
Introduction, welcome and agenda review
F. MAHFOUD (GERMANY)
07:33 - 07:48
Renal sympathetic denervation: Overview, current technical limitations and clinical results
M. SAPOVAL (FRANCE)
07:48 - 08:03
Meeting the unmet needs: Overview on new investigational device and clinical studies
E. WYFFELS (BELGIUM)
08:03 - 08:18
Safety improvement in renal sympathetic denervation procedures: lessons learned from extensive irrigated ablation experience
C. JILEK (GERMANY)
08:18 - 08:30
Debate, questions & answers
F. MAHFOUD (GERMANY)
 

Sat, 16 February

08:30 - 08:40

Welcome

• Introduction

08:30 - 08:35
Vision of the European Association of Percutaneous Cardiovascular Interventions
J. FAJADET (FRANCE) Presentation
 

Sat, 16 February

08:40 - 10:00

CE-marked device-based therapies targeting the sympathetic system-PART I

• Main session

Watch session

Chairpersons: M. LOBO (UNITED KINGDOM), F. MAHFOUD (GERMANY)
Facilitators: A. BAUMBACH (UNITED KINGDOM), E. STABILE (ITALY), J. MARCO (FRANCE)
08:40 - 10:00
Learning The Techniques: Boston Scientific Vessix Renal Denervation System™, Covidien OneShot™, CVRx Barostim neo™ , Medtronic Simplicity™, ReCor Medical PARADISE™ and St. Jude Medical EnligHTN™
E. BLESSING (GERMANY), A. PATHAK (FRANCE), J. FAJADET (FRANCE), M. LOBO (UNITED KINGDOM), M. SAPOVAL (FRANCE), T. ZELLER (GERMANY)
What information should be collected before the procedure?
M. LOBO (UNITED KINGDOM)
 

Sat, 16 February

10:25 - 12:25

CE-marked device-based therapies targeting the sympathetic system-PART II

• Main session

Watch session

Chairpersons: M. LOBO (UNITED KINGDOM), F. MAHFOUD (GERMANY)
Facilitators: A. BAUMBACH (UNITED KINGDOM), E. STABILE (ITALY), J. MARCO (FRANCE)
10:25 - 12:25
Learning the Techniques
12:10 - 12:25
What information should be collected during the procedure?
C. UKENA (GERMANY) Presentation
 

Sat, 16 February

12:30 - 13:30

Predictors of response and procedural success with irrigated and radio-frequency systems-Industry-supported lunch symposium with an unrestricted grant from COVIDIEN

• Symposium

Watch session

This video is offered by Covidien
Chairperson: S. VERHEYE (BELGIUM)
12:30 - 12:33
Introduction
S. VERHEYE (BELGIUM)
12:33 - 12:48
Predictors of response for renal denervation
E. BLESSING (GERMANY) Presentation
12:48 - 13:03
A new concept in renal denervation: The importance of excluding post-procedural vessel wall damage
E. STABILE (ITALY) Presentation
13:03 - 13:18
Irrigated radio-frequency technology for renal denervation
M.W. BERGMANN (GERMANY) Presentation
13:18 - 13:28
Panel discussion
E. BLESSING (GERMANY), E. STABILE (ITALY), M.W. BERGMANN (GERMANY)
13:28 - 13:30
Take-home messages
S. VERHEYE (BELGIUM)
 

Sat, 16 February

14:00 - 15:45

CE-marked device-based therapies targeting the sympathetic system -PART III

• Main session

Chairpersons: M. SAPOVAL (FRANCE), R. SCHMIEDER (GERMANY)
Facilitators: A. BAUMBACH (UNITED KINGDOM), E. STABILE (ITALY), J. MARCO (FRANCE)
14:00 - 15:45
Learning the Techniques : Boston Scientific Vessix Renal Denervation System™, Covidien OneShot™ CVRx Barostim neo™, Medtronic Simplicity™, ReCor Medical PARADISE™ and St. Jude Medical EnligHTN™
A. PATHAK (FRANCE), E. BLESSING (GERMANY), J. FAJADET (FRANCE), M. LOBO (UNITED KINGDOM), M. SAPOVAL (FRANCE), T. ZELLER (GERMANY)
Post-procedure antihypertensive drug management and follow-up modalities
P.F. PLOUIN (FRANCE) Presentation
Consensus: what standardised patient follow-up is needed at the European level?
P.F. PLOUIN (FRANCE)